Login
Super Investors Cormorant Asset Management, LP
CA

Cormorant Asset Management, LP

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$1.49B
Positions
60
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (52 quarters reported)

$4.49B $345M
Q4 13 Q3 16 Q2 19 Q1 22 Q4 24 Q3 26

$345M in Q4 2013 → $1.49B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
PM Parabilis Medicines Inc 10.0% Unchanged 4,615,612 $149M
PP Praxis Precision Medicines I 9.8% Trimmed 22% 500,000 $146M
Rapport Therapeutics Inc 5.5% Trimmed 7.5% 2,457,521 $82.6M
Edgewise Therapeutics Inc 5.1% Trimmed 26% 1,860,000 $75.5M
BO Bridgebio Oncology Therapeut 4.9% Unchanged 17,878,594 $73.3M
Erasca Inc 4.9% Trimmed 17% 5,000,000 $73.3M
BT Blossomhill Therapeutics Inc 4.5% New 3,614,034 $67.4M
Adlai Nortye Group Ltd 4.3% Unchanged 3,978,229 $63.7M
Dianthus Therapeutics Inc 3.0% Trimmed 33% 500,000 $44M
AS Abivax Sa 2.8% Trimmed 37% 425,000 $42.1M
Bright Minds Biosciences Inc 2.7% Trimmed 11% 800,000 $39.9M
ET Electra Therapeutics Inc 2.5% New 3,365,533 $37.9M
Moonlake Immunotherapeutics 2.2% Trimmed 11% 2,855,433 $33.4M
Oruka Therapeutics Inc 2.2% Trimmed 25% 400,000 $33.3M
AT Attovia Therapeutics Inc 2.1% New 1,788,815 $30.7M
Faeth Therapeutics Inc 2.1% Unchanged 1,028,242 $30.6M
LB Latigo Biotherapeutics Inc 2.0% New 1,815,740 $30.3M
Agomab Therapeutics Nv 1.8% Unchanged 2,465,348 $27.4M
Opus Genetics Inc 1.8% New 5,500,000 $26.6M
Climb Bio Inc 1.6% Unchanged 2,106,000 $24.2M
Freenome Inc 1.5% New 1,431,032 $22.5M
Mbx Biosciences Inc 1.5% Trimmed 32% 375,000 $22M
Biohaven Ltd 1.4% Trimmed 42% 1,510,000 $20.2M
Adarx Pharmaceuticals Inc 1.3% New 962,898 $19.2M
Eyepoint Inc 1.3% Trimmed 18% 5,750,000 $18.8M
Tango Therapeutics Inc 1.2% Trimmed 46% 700,000 $17.5M
Damora Therapeutics Inc 1.1% New 800,000 $17M
Bridgebio Pharma Inc 1.1% Trimmed 55% 250,000 $16.5M
Cue Biopharma Inc 1.1% New 625,285 $16.2M
CP Corbus Pharmaceuticals Hldgs 1.1% Unchanged 2,344,971 $16M
Bioage Labs Inc 1.1% Trimmed 6.3% 2,240,605 $15.9M
Alumis Inc 1.0% Trimmed 37% 2,075,000 $15.3M
Olema Pharmaceuticals Inc 1.0% Trimmed 19% 1,750,000 $15.1M
Pharvaris N V 1.0% Trimmed 40% 450,000 $14.3M
Helix Acquisition Corp Iii 0.9% Unchanged 1,297,500 $13.8M
Spyre Therapeutics Inc 0.7% Trimmed 44% 125,000 $11.1M
Definium Therapeutics Inc 0.7% Trimmed 31% 275,000 $10.5M
Aclaris Therapeutics Inc 0.6% New 1,750,000 $9.21M
Amylyx Pharmaceuticals Inc 0.6% Added 50% 300,000 $8.73M
Cabaletta Bio Inc 0.6% Trimmed 10% 4,500,000 $8.64M
Inhibrx Biosciences Inc 0.3% New 50,000 $5M
Kailera Therapeutics Inc 0.3% Trimmed 27% 400,000 $4.57M
Jade Biosciences Inc 0.3% New 300,000 $4.22M
Ibio Inc 0.3% Unchanged 3,570,000 $4.21M
Tarsus Pharmaceuticals Inc 0.3% Trimmed 50% 50,000 $3.93M
Roivant Sciences Ltd 0.2% Trimmed 79% 100,000 $3.66M
Enliven Therapeutics Inc 0.2% Trimmed 50% 75,000 $3.44M
Ascendis Pharma A/s 0.2% Trimmed 70% 15,000 $3.42M
Odyssey Therapeutics Inc 0.2% Trimmed 29% 125,000 $2.78M
NP Newamsterdam Pharma Company 0.2% Trimmed 80% 100,000 $2.43M
Boundless Bio Inc 0.2% Trimmed 6.0% 940,000 $2.36M
Insmed Inc 0.2% Trimmed 73% 20,000 $2.28M
BB Braveheart Bio Inc 0.1% New 70,000 $1.41M
Research Alliance Corp Iii 0.1% Trimmed 66% 125,000 $1.35M
Arcutis Biotherapeutics Inc 0.1% Trimmed 71% 50,000 $1.32M
AP Arrowhead Pharmaceuticals In 0.1% Trimmed 70% 15,000 $982K
Cogent Biosciences Inc 0.1% Trimmed 70% 30,000 $961K
Structure Therapeutics Inc 0.1% Trimmed 60% 30,000 $938K
Vaxcyte Inc 0.1% Trimmed 70% 15,000 $854K
Quince Therapeutics Inc 0.0% Unchanged 5,498 $170K

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
BT Blossomhill Therapeutics Inc New +3,614,034 +$67.4M 4.5%
PP Praxis Precision Medicines I Trimmed −140,000 −$40.8M 9.8%
ET Electra Therapeutics Inc New +3,365,533 +$37.9M 2.5%
AT Attovia Therapeutics Inc New +1,788,815 +$30.7M 2.1%
LB Latigo Biotherapeutics Inc New +1,815,740 +$30.3M 2.0%
Opus Genetics Inc New +5,500,000 +$26.6M 1.8%
Edgewise Therapeutics Inc Trimmed −650,000 −$26.4M 5.1%
Damora Therapeutics Inc Exited −1,000,000 −$26M —
AS Abivax Sa Trimmed −250,000 −$24.8M 2.8%
Freenome Inc New +1,431,032 +$22.5M 1.5%

Showing the 10 largest of 53 changes.

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
PM Parabilis Medicines Inc New +4,615,612 +$126M 6.5%
PP Praxis Precision Medicines I Trimmed −245,500 −$82.2M 11.0%
Centessa Pharmaceuticals PLC Exited −1,050,000 −$41.7M —
Mbx Biosciences Inc Trimmed −570,000 −$31.5M 1.6%
Edgewise Therapeutics Inc Trimmed −750,000 −$30.5M 5.2%
Climb Bio Inc New +2,106,000 +$27.5M 1.4%
Moonlake Immunotherapeutics Trimmed −1,275,000 −$24.8M 3.2%
Maze Therapeutics Inc Exited −750,000 −$22.4M —
Bridgebio Pharma Inc Trimmed −300,000 −$22.3M 2.1%
Olema Pharmaceuticals Inc Trimmed −1,750,000 −$21.9M 1.4%

Showing the 10 largest of 55 changes.

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
IQ Invesco Qqq Tr Exited −250,000 −$154M —
IT Ishares Tr Exited −500,000 −$123M —
SS SPDR Series Trust Exited −1,000,000 −$122M —
Erasca Inc New +5,800,000 +$93.8M 4.7%
Dianthus Therapeutics Inc New +950,000 +$79.7M 4.0%
AS Abivax Sa Trimmed −590,000 −$65.7M 4.3%
Damora Therapeutics Inc New +1,525,000 +$39.5M 2.0%
Engene Holdings Inc Exited −4,000,000 −$36.1M —
Tango Therapeutics Inc New +1,425,000 +$29.8M 1.5%
Bridgebio Pharma Inc Trimmed −350,000 −$26M 3.2%

Showing the 10 largest of 47 changes.

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
IQ Invesco Qqq Tr New +250,000 +$154M 7.1%
IT Ishares Tr New +500,000 +$123M 5.7%
SS SPDR Series Trust New +1,000,000 +$122M 5.6%
AS Abivax Sa Trimmed −600,000 −$80.9M 8.4%
Olema Pharmaceuticals Inc New +2,750,000 +$68.8M 3.2%
Arcellx Inc Exited −775,000 −$63.6M —
NP Newamsterdam Pharma Company Trimmed −1,175,000 −$41.2M 1.6%
Moonlake Immunotherapeutics Added +2,361,260 +$31.1M 2.7%
Insmed Inc Trimmed −155,000 −$27M 2.2%
Cg Oncology Inc Exited −625,000 −$25.2M —

Showing the 10 largest of 38 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
BO Bridgebio Oncology Therapeut New +17,878,594 +$207M 14.3%
Merus N V Exited −1,120,000 −$58.9M —
Moonlake Immunotherapeutics Trimmed −6,499,978 −$46.6M 1.0%
PP Praxis Precision Medicines I Trimmed −625,000 −$33.1M 3.7%
Verona Pharma PLC Exited −350,000 −$33.1M —
Helix Acquisition Corp Ii Exited −2,909,000 −$30.9M —
Ars Pharmaceuticals Inc Exited −1,100,000 −$19.2M —
Janux Therapeutics Inc Trimmed −650,000 −$15.9M 1.4%
Insmed Inc Trimmed −110,000 −$15.8M 4.3%
AS Abivax Sa Trimmed −180,000 −$15.3M 11.4%

Showing the 10 largest of 27 changes.

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Verona Pharma PLC New +350,000 +$33.1M 2.5%
Merus N V Added +380,000 +$20M 4.4%
Bridgebio Pharma Inc Trimmed −400,000 −$17.3M 5.1%
Arcellx Inc Trimmed −250,000 −$16.5M 3.9%
Axsome Therapeutics Inc Trimmed −150,000 −$15.7M 0.8%
NP Newamsterdam Pharma Company Trimmed −650,000 −$11.8M 2.9%
Janux Therapeutics Inc Trimmed −500,000 −$11.6M 2.6%
Ars Pharmaceuticals Inc Trimmed −500,000 −$8.73M 1.4%
Rhythm Pharmaceuticals Inc Exited −150,000 −$7.95M —
Onkure Therapeutics Inc Exited −1,837,739 −$7.9M —

Showing the 10 largest of 28 changes.

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Avidity Biosciences Inc Trimmed −650,000 −$19.2M 0.9%
Arcellx Inc Trimmed −250,000 −$16.4M 5.2%
Gh Research PLC Added +1,416,439 +$15.6M 1.7%
Arrivent Biopharma Inc Exited −585,462 −$15.6M —
Edgewise Therapeutics Inc Added +695,458 +$15.3M 6.8%
Ars Pharmaceuticals Inc Added +1,100,000 +$13.8M 1.5%
Bridgebio Pharma Inc Added +400,000 +$13.8M 5.2%
CP Crinetics Pharmaceuticals In Trimmed −400,000 −$13.4M 1.5%
Rhythm Pharmaceuticals Inc Trimmed −250,000 −$13.2M 0.6%
Septerna Inc Exited −560,000 −$12.8M —

Showing the 10 largest of 35 changes.

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
LP Longboard Pharmaceuticals In Exited −2,790,462 −$93M —
PP Praxis Precision Medicines I Added +823,219 +$63.4M 7.2%
Janux Therapeutics Inc Added +1,050,000 +$56.2M 6.2%
Vaxcyte Inc Trimmed −575,000 −$47.1M 1.9%
Bright Minds Biosciences Inc New +1,059,331 +$38.2M 2.1%
NP Newamsterdam Pharma Company Added +780,000 +$20M 4.6%
Onkure Therapeutics Inc New +1,837,739 +$15.8M 0.9%
Urogen Pharma Ltd Trimmed −1,250,000 −$13.3M 0.2%
Biohaven Ltd Trimmed −346,424 −$12.9M 0.1%
Septerna Inc New +560,000 +$12.8M 0.7%

Showing the 10 largest of 31 changes.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support